Clinical Trials
Research Information
Research is the driving force behind the OHF’s mission, because research provides hope to the thousands of people worldwide living with the effects of hyperoxaluria. OHF-funded research has led to groundbreaking discoveries that have unlocked the secrets of primary hyperoxaluria—providing hope, energizing science, and helping save lives around the world. We encourage people with hyperoxaluria and their families to consider taking part in clinical research trials and the patient registry to help researchers unlock the secrets of hyperoxaluria, and bring us one step closer to a cure.
Patients who volunteer to participate in clinical trials make it possible for new drugs and therapies to be developed. By enrolling in a trial or signing up for a patient registry, you will help researchers unlock the secrets of hyperoxaluria, and bring us one step closer to a cure.
Clinical Trials 101
This is an exciting time in hyperoxaluria research. Not only are there several clinical trials studying therapies to treat the underlying cause of primary hyperoxaluria, many trials are also exploring ways to treat key symptoms of both primary and enteric (or secondary) hyperoxaluria and improve quality of life. If you are new to clinical research, this section will cover the basics of clinical trials. You will learn how your or your child's safety will be protected, why you might want to participate, and how to find a clinical trial.
Academic Clinical Trials
An academic clinical trial is a clinical trial that is not funded by a pharmaceutical or biotechnology company for commercial ends, but by public-good agencies to advance medicine.
Phases of a Clinical Trial
INITIAL RESEARCH
- Funded by OHF and other organizations looking for treatments for hyperoxaluria
PHASE I
- Evaluate safety
- Determine safe dosage
- Identify side effects
PHASE II
- Test effectiveness
- Further evaluate safety
PHASE III
- Confirm effectiveness
- Monitor side effects
- Compare to other treatments
- Collect information
FDA APPROVAL
- Treatment is approved and becomes widely available
PHASE IV
- Provide additional information after approval, including risks, benefits, and best use
Drug Development Pipeline
The Oxalosis & Hyperoxaluria Foundation facilitates the development of promising new drugs, and the drug development pipeline enables you to track the progress of these potential therapies.
Nearly every hyperoxaluria drug being investigated was made possible because of the OHF’s support and its ongoing work with researchers.
Products
Company: Alnylam
Indication: PH1
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
To Patients
Company: Dicerna
Indication: PH1 & PH2
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
To Patients
Company: OxThera
Indication: PH1
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
To Patients
Company: Allena
Indication: Enteric hyperoxaluria
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
To Patients
Company: Allena
Indication: Systemic oxalosis
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
To Patients
Company: Allena
Indication: PH1
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
To Patients
Company: Orfan, a BridgeBio company
Indication: PH1
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
To Patients
Company: Novome Biotechnologies
Indication: Secondary Hyperoxaluria
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
To Patients
Company: Oxidien Pharmaceuticals
Indication: Secondary Hyperoxaluria
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
To Patients
Company: Oxidien Pharmaceuticals
Indication: Secondary Hyperoxaluria
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
To Patients
Indication |
Discovery |
Preclinical |
Phase 1 |
Phase 2 |
Phase 3 |
To Patients |
||
---|---|---|---|---|---|---|---|---|
PH1 |
|
|||||||
PH1, PH2, PH3 |
|
|||||||
PH1, PH2, PH3 |
|
|||||||
Enteric Hyperoxaluria Systemic Oxalosis Primary Hyperoxaluria Pediatric Hyperoxaluria |
|
|||||||
PH1 |
|
|||||||
Enteric Hyperoxaluria |
|
|||||||
Enteric Hyperoxaluria |
|
|||||||
Enteric Hyperoxaluria |
|
|||||||